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Background:  The  impact  of obesity  on  Japanese  patients  who  undergo  primary  percutaneous  coronary
intervention  (PCI)  remains  unclear.
Methods  and results:  Within  a single  hospital-based  cohort  in  the Shinken  Database  2004–2010,  which
comprised  all  new  patients  (n =  15 227)  who  visited  the  Cardiovascular  Institute,  we  followed  patients
who  underwent  PCI. Major  adverse  cardiac  events  (MACE)—death,  myocardial  infarction,  or target  lesion
revascularization  (TLR)—were  deﬁned  as the  composite  endpoint.  A total  of  1205  patients  were  included
in  this  study  (median  follow-up  of 1037  ±  703  days):  92 lean  [body-mass-index  (BMI)  <  20]; 640  normal-
weight  (BMI  =  20–24.9);  417  overweight  (BMI  =  25–29.9);  and  56  obese  (BMI ≥  30).  Mean  age  decreased
and  male  gender  increased  with  increasing  BMI.  Classic  coronary  risk  factors  were  more  common  in  over-
weight  and  obese  patients  than  in normal-weight  and  lean  patients.  Chronic  kidney  disease  (CKD)  was
more  common  in  lean patients  than  in  overweight  and  obese  patients.  Patients  taking  dual  antiplatelet
therapy,  statins,  beta-blockers,  and  renin–angiotensin-system  inhibitors  increased  in a BMI-dependent
manner.  Obese  patients  had  a signiﬁcantly  lower  frequency  of  MACE,  all-cause  death,  cardiac  death,  and
hospital  admission  for heart  failure  than  lean  patients.  Multivariate  analysis  showed  that BMI category
was  independently  associated  with  all-cause  death  after  PCI.
Conclusion:  Over-weight  and  obese  patients  were  independently  associated  with  favorable  long-term
clinical  outcomes  after  PCI, suggesting  that  obesity  paradox  was  applicable  to  Japanese  patients  after  PCI
in  real-world  clinical  setting.
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ntroduction
Obesity is strongly associated with increased morbidity and
ortality, as well as with cardiovascular risk factors including dia-
etes mellitus, hypertension, and dyslipidemia [1–3]. However,
umerous studies conducted in Western countries have suggested
n “obesity paradox” after percutaneous coronary intervention
PCI), whereby obese patients had better clinical outcomes com-
ared with normal-weight patients after PCI [4–7]. Because of a
esternized life style, the number of obese citizens in Japan is
apidly increasing, and obesity has become a pandemic public
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health problem. In reﬂection of Western countries’ wide variations
in ethnicity, geographic location, social health care systems, and
treatment strategies [8–14], it has been suggested that clinical out-
comes of coronary artery disease (CAD) in Japan may differ from
those in Western countries. Furthermore, because PCI is preferred
and widely performed in Japanese CAD patients, the clinical charac-
teristics and outcomes of Japanese CAD patients were thought to be
different from those in Western countries. Therefore, the evidence
for contemporary prognosis of Japanese CAD patients treated by
PCI should be established. Kosuge et al. reported that overweight
and obese patients had better in-hospital outcomes after PCI for
ST-segment elevation acute myocardial infarction (MI) [15]. How-
ever, clinical data assessing the impact of obesity on outcomes of
Japanese CAD patients after PCI are limited. Accordingly, we  have
conducted a hospital-based cohort study of the Shinken Database
since 2004 to investigate the prevalence and prognosis of patients
with cardiovascular diseases in Japan [16]. In the present study,
vier Ltd. All rights reserved.
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Echocardiography ﬁndingsH. Kaneko et al. / Journal 
e aimed to examine the relationship between obesity and the
ong-term clinical outcome of Japanese patients treated by PCI.
lthough the population is restricted to a particular setting, the
ata provide us with the most recent real-world clinical evidence
egarding the clinical outcomes of Japanese CAD patients after
CI.
ethods
tudy patients and protocols
The Shinken Database was established to include all new
atients visiting the Cardiovascular Institute Hospital in Tokyo,
apan (“Shinken” is an abbreviated name in Japanese for the name
f the hospital) and excludes patients with active cancer and any
oreign travelers. The principle aim of this hospital-based database
s a survey of the prevalence and prognosis of cardiovascular dis-
ases in the urban areas of Japan [17]. The registry started in June
004 and since then, patients have been continually registered to
he database annually.
The data in the present study were derived from this database
etween June 2004 and March 2011 (Shinken Database 2004–2010)
nd included 15 227 new patients. Among them, all patients who
nderwent PCI (n = 1214) were enrolled; those patients (n = 9) who
ad no available data for height and body weight were excluded.
inally, 1205 patients were examined in this study. The following
ata were obtained: age; gender; height; body weight; prior his-
ory of MI,  PCI, and CABG; coronary risk factors; laboratory data;
nd medications at primary PCI. Echocardiography was routinely
erformed at PCI.
atient follow-up
The health status and the incidence of cardiovascular events and
ortality are maintained in the database by being linked to the
edical records of the hospital, as well as by study documents of
rognosis sent once per year to those who stopped hospital visits
r who were referred to other hospitals.
In the present data analysis, follow-up data after April 1, 2011
ere excluded. Therefore the end of the follow-up period was
eﬁned as one of the following: (1) the date of death, if the date
as prior to March 31, 2011; (2) the ﬁnal hospital visit or the ﬁnal
esponse to our study documents of prognosis with conﬁrmation
hat the patient was alive before March 31, 2011; or (3) March
1, 2011, when the date of death, the ﬁnal hospital visit, or the
nal response to our study documents of prognosis was  later than
pril 1, 2011.
thics
The ethical committee at the Cardiovascular Institute granted
thical permission for this study and all patients gave written
nformed consent.
eﬁnitions
We  conﬁrmed the deaths of study patients either with the
edical records of our hospital or with the information obtained
rom follow-up. An estimated glomerular ﬁltration rate (eGFR) was
alculated by using the GFR equation used for the Japanese popu-
ation: GFR = 194 × (serum creatinine)−1.094 × (age)−0.287 × (0.739 if
emale) [18]. Chronic kidney disease (CKD) was deﬁned as a base-
ine eGFR < 60 mL/min/1.73 m2 [19]. BMI  was calculated at initial
CI by dividing the patient’s measured weight (in kg) by the square
f the height (in m).  Patients were divided into 4 groups according
o baseline BMI: lean (<20 kg/m2), normal weight (20–24.9 kg/m2),diology 62 (2013) 18–24 19
overweight (25–29.9 kg/m2), and obese (≥30 kg/m2) [3,20]. Target
lesion revascularization (TLR) was  deﬁned as any repeat revascula-
rization procedure (percutaneous or surgical) of the original target
lesion site, which includes the stented segment plus edge segments
(typically 5 mm proximal and distal to the stent). Major adverse
cardiac event (MACE) was  deﬁned as a composite endpoint that
included all-cause death, MI,  or TLR.
Statistical analysis
In the patients’ background, the categorical and consecutive
data are presented as number (%) and mean ± standard devia-
tion, respectively. We  made comparisons by one-way analysis
of variance (ANOVA) for continuous variables, and the statis-
tical signiﬁcance of difference was calculated using the Tukey
t-test. Chi-square analysis was  used to compare categorical
variables. Long-term event-free survival was  estimated using
Kaplan–Meier curves and the log-rank (Mantel–Cox) test to assess
the signiﬁcance of differences between lean, normal weight, over-
weight, and obese patients. Univariate Cox regression analysis
was used to identify the cofactors with signiﬁcant effects on all-
cause death. Multivariate Cox regression analysis was  performed
to determine the independent prognostic factors for all-cause
death. A probability value of < 0.05 was  considered to indicate
a statistically signiﬁcant difference. These analyses were per-
formed using SPSS (SPSS Inc., Chicago, IL, USA) version 19.0
software.
Results
Patients’ characteristics
The 4 groups were lean (body mass index [BMI] < 20 kg/m2), 92
patients (8%); normal weight (BMI = 20–24.9 kg/m2), 640 patients
(53%); overweight (BMI = 25–29.9 kg/m2), 417 patients (35%); and
obese (BMI ≥ 30 kg/m2), 56 patients (5%). The median follow-up
period was  1037 ± 703 days. Mean age decreased and male gen-
der increased with increasing BMI. Prevalence of stable angina
pectoris and acute coronary syndrome (ACS) (non-ST elevation
ACS and ST elevation myocardial infarction) were comparable
between the 4 groups. The classic coronary risk factors of hyperten-
sion, diabetes mellitus, dyslipidemia, hyperuricemia, and cigarette
smoking were more common in overweight and obese patients
than in normal weight and lean patients. In contrast, CKD and
chronic obstructive pulmonary disease (COPD) were more common
in lean patients than in overweight and obese patients. Low-
density lipoprotein cholesterol (LDL), triglyceride (TG), glucose,
and HbA1c increased with increasing BMI, whereas high-density
lipoprotein cholesterol (HDL) decreased with increasing BMI.
The number of patients taking dual antiplatelet therapy (DAPT)
decreased and the number taking statins and calcium-channel
blockers (CCB)s increased with increasing BMI. Lean patients were
more likely to be taking vasodilators including nitrate and nico-
randil. There was a trend toward higher rates of beta-blocker
and renin–angiotensin system inhibitor (RAS-I)s use with increas-
ing BMI, but the difference did not reach statistical signiﬁcance
(Table 1).Echocardiography performed at initial PCI showed the left
ventricular ejection fraction (LVEF) to be comparable among the
4 groups (Table 1).
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Table 1
Patient characteristics.
Lean (n = 92) Normal weight (n = 640) Over weight (n = 417) Obesity (n = 56) p-Value
BMI(kg/m2) 18.4 ± 1.3 22.9 ± 1.3 26.9 ± 1.3 31.9 ± 1.8 <0.001
Age  (years) 70.5 ± 12.1 66.8 ± 10.1 63.2 ± 10.2 55.2 ± 10.9 <0.001
Male  gender 56/92 (60.9) 521/640 (81.4) 366/417 (87.8) 52/56 (92.9) <0.001
SAP  50/92 (54.3) 408/640 (63.8) 255/417 (61.2) 34/56 (60.7) 0.350
ACS  42/92 (45.7) 232/640 (36.3) 162/417 (38.8) 22/56 (39.3) 0.350
Non-STE-ACS 19/92 (20.7) 119/640 (18.6) 85/417 (20.4) 10/56 (17.9) 0.873
STEMI  23/92 (25.0) 113/640 (17.7) 77/417 (18.5) 12/56 (21.4) 0.369
Prior  MI 7/92 (7.6) 75/640 (11.7) 44/417 (10.6) 7/56 (12.5) 0.653
Prior  PCI 14/92 (15.2) 65/640 (10.2) 44/417 (10.6) 6/56 (10.7) 0.538
Prior  CABG 3/92 (3.3) 24/640 (3.8) 19/417 (4.6) 1/56 (1.8) 0.733
Hypertension 45/92 (48.9) 392/640 (61.3) 299/417 (71.7) 39/56 (69.6) <0.001
Diabetes mellitus 19/92 (20.7) 214/640 (33.4) 149/417 (35.7) 27/56 (48.2) 0.005
Dyslipidemia 36/92 (39.1) 362/640 (56.6) 278/417 (66.7) 40/56 (71.4) <0.001
Hyperuricemia 15/92 (16.3) 141/640 (22.0) 127/417 (30.5) 19/56 (33.9) 0.001
Cigarette smoking 23/92 (25.0) 214/640 (33.4) 174/417 (41.7) 35/56 (62.5) <0.001
Family history 7/92 (7.6) 100/640 (15.6) 73/417 (17.5) 12/56 (21.4) 0.077
CKD  39/92 (42.4) 206/640 (32.2) 129/417 (30.9) 11/56 (19.6) 0.033
COPD  4/92 (4.3) 9/637 (1.4) 1/417 (0.2) 0/56 (0.0) 0.007
Total  cholesterol (mg/dL) 188.8 ± 42.9 192.0 ± 37.7 192.3 ± 38.5 201.7 ± 45.0 0.254
LDL  (mg/dL) 105.0 ± 33.9 112.2 ± 32.3 115.0 ± 32.6 122.0 ± 40.0 0.011
HDL  (mg/dL) 60.7 ± 16.1 52.5 ± 15.8 47.1 ± 11.9 45.5 ± 9.1 <0.001
TG  (mg/dL) 104.0 ± 103.7 143.5 ± 96.5 168.7 ± 121.2 195.7 ± 147.3 <0.001
Glucose (mg/dL) 130.0 ± 43.9 132.5 ± 54.0 134.2 ± 54.9 160.0 ± 78.8 0.004
HbA1c (%) 5.7 ± 1.0 6.1 ± 1.2 6.2 ± 1.3 6.7 ± 1.6 <0.001
LVEF  (%) 59.9 ± 16.2 62.4 ± 13.2 61.3 ± 11.7 58.7 ± 12.7 0.069
DAPT  81/92 (88.0) 613/640 (95.8) 402/417 (96.6) 53/56 (94.6) 0.004
Anticoagulant therapy 7/92 (7.6) 55/640 (8.6) 28/417 (6.7) 3/56 (5.4) 0.633
Statins 42/92 (45.7) 375/640 (58.6) 274/417 (65.7) 42/56 (75.0) <0.001
Beta-blockers 29/92 (31.5) 239/640 (37.3) 152/417 (36.5) 27/56 (48.2) 0.232
ACE-Is 17/92 (18.5) 103/640 (16.1) 66/417 (15.8) 9/56 (16.1) 0.940
ARBs  28/92 (30.4) 236/640 (36.9) 176/417(42.2) 26/56(46.4) 0.068
RAS-I  43/92 (46.7) 331/640 (51.7) 237/417 (56.8) 35/56 (62.5) 0.103
CCBs  28/92 (30.8) 268/640 (41.9) 212/417 (50.8) 30/56 (53.6) <0.001
Vasodilators 47/92 (51.1) 240/640 (37.5) 124/417 (29.7) 20/56 (35.7) 0.001
Diuretics 13/92 (14.1) 85/640 (13.3) 47/417 (11.3) 7/56 (12.5) 0.769
Aldosterone antagonist 3/92 (3.3) 35/640 (5.5) 26/417 (6.2) 2/56 (3.6) 0.631
Antidiabetic drugs 9/92 (9.8) 131/640 (20.5) 79/417 (18.9) 18/56 (32.1) 0.009
Thiazolidinediones 1/92 (1.1) 23/640 (3.6) 12/417 (2.9) 4/56 (7.1) 0.223
Insulin  3/92 (3.3) 18/640 (2.8) 16/417 (3.8) 1/56 (1.8) 0.746
LMT  7/92 (7.6) 44/640 (6.9) 17/417 (4.1) 3/56 (5.4) 0.250
MVD  53/92 (57.6) 377/640 (58.9) 262/417 (62.8) 32/56 (57.1) 0.548
BMI, body-mass index; SAP, stable angina pectoris; STE, ST-elevation; ACS, acute coronary syndrome; Prior MI,  prior history of myocardial infarction; Prior PCI,  prior history
of  percutaneous coronary intervention; Prior CABG, prior history of coronary artery bypass graft; CKD, chronic kidney disease; COPD, chronic obstructive pulmonary disease;
LDL,  low-density lipoprotein cholesterol; HDL, high-density lipoprotein cholesterol; TG,  triglyceride; LVEF, left ventricular ejection fraction; DAPT, dual antiplatelet therapy;
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ngiographic ﬁndings
Coronary angiography performed at initial PCI showed that the
revalence of left main trunk disease (LMT) and multivessel disease
MVD) was comparable among the 4 groups (Table 1).
linical outcomes
The occurrence of adverse cardiac events in each group is listed
n Table 2. Kaplan–Meier curves and the log-rank test revealed
hat overweight and obese patients had signiﬁcantly lower inci-
ence of MACE (p = 0.002), all-cause death (p < 0.001), cardiac death
p = 0.001), heart failure death (p = 0.004), and hospital admission
or heart failure (p < 0.001) during the observation period (Fig. 1).
he incidence of MI  and TLR was comparable among the 4 groups
Fig. 1).
redictors of death in CAD patients after PCIIn the univariate Cox regression models, age, BMI category, ACS,
istory of MI,  dyslipidemia, cigarette smoking, family history of
AD, CKD, levels of total cholesterol, LDL, triglyceride (TG), andensin II receptor blocker; RAS-I, renin–angiotensin system inhibitor; CCB, calcium
glucose, LVEF, use of statins, diuretics, and aldosterone antagonists,
left main trunk (LMT) disease, and MVD  were associated with all-
cause death in patients after PCI (Table 3). Risk of BMI category
was adjusted by step wise multivariate Cox regression analysis
including signiﬁcant predictors in the univariate models, and the
ﬁnal multivariate model showed that BMI  category was indepen-
dently associated with all-cause death after PCI, as well as poor
LVEF, CKD, a high glucose level, and the absence of statin treatment
(Table 4).
Discussion
The present study showed that overweight and obese patients
were at lower long-term risk of all-cause death, cardiac death, heart
failure admission, and MACE after PCI. Obese patients had a higher
prevalence of traditional cardiovascular risk factors and guideline-
recommended medical therapy compared with non-obese patients,
while the latter group was  older and more likely to have renal
dysfunction.
It should be noted that about 70% of the patients in those stud-
ies were overweight or obese in the previous studies conducted
in Western countries, whereas 39% in the present study fell into
H. Kaneko et al. / Journal of Cardiology 62 (2013) 18–24 21
Table  2
Clinical outcomes.
Lean (n = 92) Normal weight (n = 640) Over weight (n = 417) Obesity (n = 56) p-Value
MACE 27/92 (29.3) 143/640 (22.3) 73/417 (17.5) 8/56 (14.3) 0.027
All-cause death 15/91 (16.3) 31/640 (4.8) 9/417 (2.2) 2/56 (3.6) <0.001
Cardiac death 5/92 (5.4) 7/640 (1.1) 4/417 (1.0) 0/56 (0.0) 0.004
Heart  failure 4/92 (4.3) 5/640 (0.8) 2/417 (0.5) 0/56 (0.0) 0.004
MI  1/92 (1.1) 1/640 (0.2) 2/417 (0.5) 0/56 (0.0) 0.450
VT/VF 0/92 (0.0) 1/640 (0.2) 0/417 (0.0) 0/56 (0.0) 0.829
MI  1/92 (1.1) 8/640 (1.3) 11/417 (2.6) 1/56 (1.8) 0.378
Readmission for heart failure 10/92 (10.9) 22/640 (3.4) 14/417 (3.4) 1/56 (1.8) 0.004
TLR  15/92 (16.3) 115/640 (18.0) 62/417 (14.9) 6/56 (10.7) 0.365
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ata  are expressed as counts (percentage).
hose categories. The prevalence of overweight and obese sub-
ects was similar to a previous study conducted in Japan [15];
herefore, this phenomenon reﬂected demographic differences in
ody weight between Japan and Western countries. Although there
as the difference in the prevalence of obesity between subjects
n Western countries and Japan, the impact of obesity on long-
erm clinical outcomes after PCI was similar. We  found that obese
atients had higher rates of traditional cardiovascular risk fac-
ors such as hypertension, diabetes mellitus, and dyslipidemia,
hich also was consistent with the results of previous studies con-
ucted in Western countries and Japan [1–3,15,21–23]. Despite
ig. 1. Kaplan–Meier curves for major adverse cardiac event (MACE)-free survival rate (A), 
nfarction (MI)-free survival rate (D), heart failure admission-free survival rate (E), and tardia and/or ventricular ﬁbrillation; TLR, target lesion revascularization.
such adverse background clinical characteristics, obese patients
had favorable long-term outcomes. In contrast, lean patients had
fewer traditional cardiovascular risk factors but the highest long-
term mortality. Lean patients were more often elderly and female
and had higher prevalence of CKD. This tendency was  also similar
to the previous studies in Western countries and Japan described
above. Numerous studies have shown that elderly patients have
poor clinical outcomes after PCI [24–26]. Moreover, although
gender-based differences have decreased in the stent era, previous
studies found that female gender may  be associated with worse
clinical outcomes after PCI [27–29]. CKD increased cardiovascular
all-cause death-free survival rate (B), cardiac death-free survival rate (C), myocardial
rget lesion revascularization (TLR)-free survival rate (F).
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Table 3
Predictors for all-cause death (univariate models).
p-Value Hazard ratio 95% CI
BMI  category
Lean (Reference)
Normal weight <0.001 0.235 0.124–0.443
Over weight <0.001 0.120 0.052–0.274
Obese 0.027 0.102 0.013–0.773
Age  (years) <0.001 1.080 1.052–1.109
Male sex 0.085 0.604 0.341–1.072
Obesity 0.003 0.363 0.188–0.702
ACS 0.020 1.834 1.102–3.050
Prior MI  0.027 2.044 1.085–3.850
Prior PCI 0.315 1.464 0.695–3.083
Prior CABG 0.559 1.414 0.442–4.521
Hypertension 0.261 0.747 0.449–1.243
Diabetes mellitus 0.153 1.455 0.871–2.431
Dyslipidemia 0.002 0.445 0.264–0.750
Hyperuricemia 0.173 1.459 0.847–2.515
Cigarette smoking 0.001 0.341 0.177–0.657
Family history 0.037 0.340 0.123–0.937
CKD <0.001 4.462 2.635–7.558
Total cholesterol (mg/dL) 0.008 0.990 0.982–0.997
LDL cholesterol (mg/dL) 0.008 0.988 0.979–0.997
HDL cholesterol (mg/dL) 0.397 1.007 0.991–1.023
TG  (mg/dL) 0.004 0.993 0.989–0.998
Glucose (mg/dL) <0.001 1.007 1.004–1.010
HbA1c (%) 0.437 1.081 0.889–1.314
LVEF (%) <0.001 0.944 0.930–0.958
DAPT 0.199 0.574 0.246–1.338
Anticoagulant therapy 0.724 0.833 0.302–2.297
Statins <0.001 0.275 0.155–0.489
Beta-blockers 0.300 1.309 0.787–2.179
ACE-Is 0.931 0.970 0.490–1.921
ARBs 0.436 0.803 0.462–1.396
RAS-I 0.511 0.843 0.507–1.403
CCBs 0.072 0.606 0.352–1.045
Vasodilators 0.326 1.292 0.775–2.153
Diuretics <0.001 4.294 2.506–7.357
Aldosterone antagonist <0.001 4.125 2.134–7.975
Antidiabetic drugs 0.674 0.864 0.438–1.705
Thiazolidinediones 0.718 1.239 0.388–3.963
Insulin 0.141 2.142 0.776–5.911
LMT 0.005 2.936 1.391–6.195
MVD  0.008 2.291 1.239–4.235
BMI, body-mass index; ACS, acute coronary syndrome; Prior MI,  prior history of
myocardial infarction; Prior PCI,  prior history of percutaneous coronary inter-
vention; Prior CABG, prior history of coronary artery bypass graft; CKD, chronic
kidney disease; LDL, low-density lipoprotein; HDL, high-density lipoprotein; TG,
triglyceride; DAPT, dual antiplatelet therapy; Statin, HMG-CoA inhibitor; ACE-I,
angiotensin-converting enzyme inhibitor; ARB, angiotensin II receptor blocker; RAS-
I
t
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f,  renin–angiotensin system inhibitors; CCBs, calcium channel blocker; LMT, left main
runk; MVD, multivessel disease; CI,  conﬁdence interval.
ortality and morbidity risk [30,31]. Furthermore, patients with
AD have been believed to more frequently have impaired renal
unction, and reduced renal function may  result in worse clin-
cal outcomes after revascularization therapy [19,31–34]. These
able 4
redictors for all-cause death (multivariate model).
p-Value Hazard ratio 95% CI
BMI  category
Lean (Reference)
Normal weight 0.001 0.317 0.164–0.613
Over weight 0.001 0.214 0.090–0.513
Obese 0.083 0.150 0.018–1.284
Age  0.006 1.04 1.011–1.070
CKD 0.008 2.265 1.240–4.139
Glucose 0.004 1.005 1.002–1.009
LVEF <0.001 0.960 0.944–0.976
Statins 0.031 0.498 0.264–0.939
MI, body-mass index; CKD, chronic kidney disease; LVEF, left ventricular ejection
raction; Statin,  HMG-CoA inhibitor; CI,  conﬁdence interval.diology 62 (2013) 18–24
differences in background clinical characteristics may  have pro-
vided the survival beneﬁt in the obese patients. In addition, the
lean patients had higher rates of heart failure admission and heart
failure death during the follow-up periods although left ventricu-
lar function was  comparable between the 4 groups. Various studies
have suggested that obesity paradox applied not only for patients
with CAD, but also those with heart failure [35–39]. These ﬁnd-
ings should reassure physicians that lean patients after PCI might
need careful follow-up to prevent adverse clinical outcomes includ-
ing the development of heart failure. Optimal medical therapy
improves morbidity and mortality in CAD and remains the corner-
stone of treatment [40–42]. The COURAGE trial reminded us of the
need for careful attention to established medical treatment and risk
factor modiﬁcation [40]. Despite having a higher risk proﬁle at the
time of PCI, the use of multiple evidence-based classes of cardiovas-
cular medications––antiplatelet, lipid-lowering, beta-blockers, and
angiotensin-converting enzyme inhibitors––was associated with
favorable clinical outcomes [41]. Studies to date have reported on
short-term differences in cardiac medications after PCI according
to BMI. Diercks et al. reported that obese patients with ACS receive
more aggressive treatment and, except for the extremely obese,
have fewer adverse outcomes compared with underweight and
normal-weight patients [43]. Steinberg et al. found that increased
BMI  was  associated with an increased use of guideline-based med-
ical therapy both in-hospital and at discharge in 130 139 patients
hospitalized for CAD [44]. Likewise, Lanceﬁeld et al. recently
demonstrated that obese patients had a higher rate of guideline-
based medication use at 12 months after PCI, coinciding with
the improvement in MACE and mortality [45]. Among the opti-
mal  medical treatment, statins are the most promising agents for
the treatment of CAD and their effects have been studied exten-
sively [46–48]. In Western countries, statins are administered to
CAD patients in 80–90% of cases [49]. In contrast, only 50.4% of
the patients included in the present study received statins after
PCI. Although statins were prescribed for patients, they were often
not taken or discontinued for different reasons. In the present
study, the absence of statin treatment was an independent pre-
dictor for all-cause death of patients after PCI and the number
of patients taking statins increased with increasing BMI. There-
fore, there may  be room for further improvement in long-term
clinical outcomes of lean patients by aggressive statin treatment.
Unfortunately, we did not have the detail of non-use of statin treat-
ment and the dropout rate from statin treatment in this study.
Further study will be needed for clarifying the impact of statin
treatment on long-term clinical outcomes of lean CAD patients after
PCI.
The use of BMI  as a measure of obesity may  not sufﬁciently char-
acterize the impact of body size. Because BMI  does not discriminate
adipose tissue content, higher BMI  values may  in some cases sim-
ply reﬂect greater-than-lean body mass composition. Gelber et al.
examined associations between anthropometric measures using
BMI, waist circumference, waist-to-hip ratio, waist-to-height ratio,
and incidence of cardiovascular disease. They found that waist-to-
height ratio demonstrated statistically the best model ﬁt and the
strongest associations with cardiovascular disease [50]. BMI has
been extensively studied and provides the most useful population-
level measure of obesity because it is the same for both sexes and
because the World Health Organization endorses its use as a mea-
sure of obesity by using BMI  to deﬁne and classify obesity. A causal
link between obesity and improved clinical outcomes is biologi-
cally plausible. Adipose tissue is increasingly being recognized as an
active endocrine organ [51–53]; however, the effects of adipokines
on metabolic risk factors, coronary arteries, and atherosclerosis
are incompletely understood. Further study is needed to elucidate
the complicated associations between adipokines and the obesity
paradox.
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We  recognize that the present study had several limitations.
his study was based on a single center’s experience, and the num-
er of study patients was small. The statistical power might not be
trong enough for any negative data to be conclusive. Accordingly,
ore studies with a larger population size are needed. Although
atients with COPD were relatively small in number, the prevalence
f COPD was higher in lean patients, which might contribute to the
igher mortality of lean patients. As the lean patients were older
nd had higher frequency of CKD, it might be possible that the lean
atients had more severe CAD compared with the normal-weight
nd the obese patients. Further study will be needed to clarify the
ssociation of the severity of CAD and the obesity paradox after PCI.
In conclusion, independent of age, renal function, and optimal
edication use, overweight and obesity were independently asso-
iated with favorable clinical outcomes of Japanese CAD patients
fter PCI. The results suggest that the obesity paradox is applica-
le to the real-world Japanese clinical setting, similar to previous
eports in Western countries.
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